Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Veenstra

Showing results (1-10 of 284) with videos related to

Pageof 29
Sort By:
Journal of Thrombosis and Haemostasis : JTH|July 26, 2007
The cost-effectiveness of warfarin pharmacogenomicsD L Veenstra
Pharmacogenetics|July 13, 2004
Bringing genomics to the bedside: a cost-effective pharmacogenomic test?David L Veenstra
Clinical Pharmacology and Therapeutics|November 14, 2015
The value of routine pharmacogenomic screening-Are we there yet? A perspective on the costs and benefits of routine screening-shouldn't everyone have this done?D L Veenstra
Pharmacoeconomics|October 15, 2008
A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis BD Eldon Spackman, David L Veenstra
JAMA|September 22, 2011
Evolving research and stakeholder perspectives on pharmacogenomicsAmber L Beitelshees, David L Veenstra
Pharmacogenetics and Genomics|January 21, 2006
Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysisLisa M Meckley, David L Veenstra
Pharmacotherapy|August 30, 2008
Warfarin pharmacogeneticsNita A Limdi, David L Veenstra
Journal of Clinical Epidemiology|December 10, 2009
Expectations, validity, and reality in pharmacogeneticsNita A Limdi, David L Veenstra
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 1, 2020
Economic value of exome sequencing for suspected monogenic disordersBart S Ferket, David L Veenstra
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|February 20, 2015
A patient with syncope: a shocking experienceL Veenstra, M Oosting, L Baur
Pageof 29

Showing results (1-10 of 284) with videos related to

Sort By:
Pageof 29
Journal of Thrombosis and Haemostasis : JTH|July 26, 2007
The cost-effectiveness of warfarin pharmacogenomicsD L Veenstra
Pharmacogenetics|July 13, 2004
Bringing genomics to the bedside: a cost-effective pharmacogenomic test?David L Veenstra
Clinical Pharmacology and Therapeutics|November 14, 2015
The value of routine pharmacogenomic screening-Are we there yet? A perspective on the costs and benefits of routine screening-shouldn't everyone have this done?D L Veenstra
Pharmacoeconomics|October 15, 2008
A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis BD Eldon Spackman, David L Veenstra
JAMA|September 22, 2011
Evolving research and stakeholder perspectives on pharmacogenomicsAmber L Beitelshees, David L Veenstra
Pharmacogenetics and Genomics|January 21, 2006
Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysisLisa M Meckley, David L Veenstra
Pharmacotherapy|August 30, 2008
Warfarin pharmacogeneticsNita A Limdi, David L Veenstra
Journal of Clinical Epidemiology|December 10, 2009
Expectations, validity, and reality in pharmacogeneticsNita A Limdi, David L Veenstra
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 1, 2020
Economic value of exome sequencing for suspected monogenic disordersBart S Ferket, David L Veenstra
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|February 20, 2015
A patient with syncope: a shocking experienceL Veenstra, M Oosting, L Baur
Pageof 29